<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Alpha-amino-3-hydroxy-5-<z:chebi fb="36" ids="29309">methyl</z:chebi>-4-isoxazolepropionic acid (AMPA) receptor inhibition has been hypothesized to provide neuroprotective efficacy after <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> on the basis of the activity in experimental <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> models of a variety of compounds with varying selectivity for AMPA over other <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> receptor subtypes </plain></SENT>
<SENT sid="1" pm="."><plain>CP-465,022 is a new, potent, and selective noncompetitive AMPA receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>The present study investigated the ability of this compound to reduce <z:hpo ids='HP_0002529'>neuronal loss</z:hpo> after experimental <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> to probe the neuroprotective potential of AMPA receptor inhibition </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: To demonstrate that CP-465,022 gains access to the brain, the effects of systemic administration of CP-465,022 were investigated on AMPA receptor-mediated electrophysiological responses in hippocampus and on chemically induced <z:hpo ids='HP_0001250'>seizures</z:hpo> in rats </plain></SENT>
<SENT sid="4" pm="."><plain>The compound was then investigated for neuroprotective efficacy in rat global and focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> models at doses demonstrated to be maximally effective in the electrophysiology and <z:hpo ids='HP_0001250'>seizure</z:hpo> models </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: CP-465,022 potently and efficaciously inhibited AMPA receptor-mediated hippocampal synaptic transmission and the induction of <z:hpo ids='HP_0001250'>seizures</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>However, at comparable doses, CP-465,022 failed to prevent CA1 neuron loss after brief global <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> or to reduce <z:mpath ids='MPATH_124'>infarct</z:mpath> volume after temporary middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Given the high selectivity of CP-465,022 for AMPA over kainate and <z:chebi fb="0" ids="31882">N-methyl-D-aspartate</z:chebi> subtypes of <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> receptors, the lack of neuroprotective efficacy of the compound calls into question the neuroprotective efficacy of AMPA receptor inhibition after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
</text></document>